<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563562</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1002</org_study_id>
    <nct_id>NCT01563562</nct_id>
  </id_info>
  <brief_title>Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function</brief_title>
  <official_title>A Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic profile of bardoxolone methyl
      following a single oral dose of 20 mg bardoxolone methyl in subjects with mild, moderate, and
      severe hepatic impairment, as compared to healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Bardoxolone Methyl 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone Methyl</intervention_name>
    <description>Oral, Single dose</description>
    <arm_group_label>Bardoxolone Methyl 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects

               1. Male or female subjects between 18 and 70 years, inclusive; must meet all of the
                  following criteria to be included in the study:

               2. Willing to practice method of birth control (both males who have partners of
                  childbearing potential and females of childbearing potential) during screening,
                  while taking study drug and for at least 30 days after the last dose of study
                  drug is ingested;

               3. Female subjects of childbearing potential must be non-pregnant and non-lactating
                  and have a negative serum pregnancy test result before enrollment into the study;

               4. Body mass index (BMI) between 18 and 37 kg/m2;

               5. Willing and able to give written informed consent for study participation;

               6. Willing and able to cooperate with all aspects of the protocol.

                  Subjects with hepatic impairment

               7. Have documented evidence of hepatic cirrhosis by biopsy, nuclear scan, CT, MRI,
                  ultrasound, or other clinically acceptable methods; must meet all of the
                  following criteria to be included in the study:

               8. Be classified as Child-Pugh class A (mild), B (moderate), or C (severe). (See
                  Appendix A for Child-Pugh system.)

        Exclusion Criteria:

          -  All subjects

               1. Participated in another clinical trial of an investigational drug (or a medical
                  device) within 30 days of Study Day -1, or are currently participating in another
                  trial of an investigational drug (or a medical device); with any of the following
                  conditions or characteristics must be excluded from the study:

               2. Known hypersensitivity to any component in the formulation of the study drug,
                  bardoxolone methyl;

               3. Any medical or dental procedure, no matter how minor, that is planned or
                  anticipated to occur during the conduct of the study;

               4. History of drug or alcohol abuse or dependence within the last year;

               5. Donation or receipt of blood or blood components within the 4 weeks prior to
                  Study Day -1. The investigator should instruct subjects who participate in this
                  study not to donate blood or blood components for 4 weeks after the completion of
                  the study;

               6. Abnormal screening ECG which is interpreted by the investigator to be clinically
                  significant;

               7. A positive test for drug(s) of abuse (ethanol, amphetamines, benzodiazepines,
                  barbiturates, cocaine, opiates, or cannabinoids) at the screening or the Day -1
                  visit, unless the positive drug screen is for a subject with hepatic impairment
                  for a prescription drug and is approved by the principal investigator;

               8. Female subjects who are planning a pregnancy or are pregnant or lactating;

               9. Deemed by the investigator to be inappropriate for this study, including subjects
                  who are unable to communicate with the investigator due to language problems,
                  poor mental development, or impaired cerebral function;

              10. Any concurrent clinical conditions that in the judgment of the investigator could
                  either potentially pose a health risk to the subject while involved in the study
                  or could potentially influence the study outcome;

              11. Positive test results for human immunodeficiency virus type 1 or 2 antibody at
                  screening;

              12. Have an estimated creatinine clearance &lt; 60 mL/min on Study Day -1 using the
                  Cockcroft-Gault equation (Appendix B);

              13. Any condition possibly affecting absorption, distribution, metabolism or
                  excretion of drugs that may confound the analyses conducted in this study (for
                  example: previous surgery on the gastrointestinal tract that includes removal of
                  parts of stomach, bowel, liver, gall bladder, pancreas, venacaval shunts, or
                  transjugular intrahepatic portosystemic shunts]).

                  Subjects with hepatic impairment

              14. Sustained systolic blood pressure &gt; 160 mmHg or &lt; 100 mmHg or a diastolic blood
                  pressure &gt; 100 mmHg at screening or baseline measured after 5 minutes in a
                  sitting position; who have any of the following conditions or characteristics
                  must be excluded from the study:

              15. A pulse rate at rest in a sitting position of &lt; 45 bpm or &gt; 105 bpm;

              16. Documented evidence of primary biliary cirrhosis;

              17. Evidence of recent (two months or less) or current gastrointestinal bleeding;

              18. Platelet counts &lt;50,000 or &gt;450,000.

                  Subjects with normal hepatic function

              19. Sustained systolic blood pressure &gt; 150 mmHg or &lt; 100 mmHg or a diastolic blood
                  pressure &gt; 95 mmHg at screening measured after 5 minutes in a sitting position;
                  who have any of the following conditions or characteristics must be excluded from
                  the study:

              20. A pulse rate at rest in a sitting position of &lt; 45 bpm or &gt; 100 bpm;

              21. Evidence or history of or concurrent clinically significant allergic (except for
                  untreated, asymptomatic, seasonal allergies at time of dose administration),
                  hematological, endocrine, immunological, renal, pulmonary, gastrointestinal,
                  cardiovascular, hepatic, psychiatric, or neurological disease that in the
                  judgment of the investigator could potentially either pose a health risk to the
                  subject during the study or influence the study outcome;

              22. Evidence of hepatic or biliary dysfunction including elevation of total
                  bilirubin, direct bilirubin, aspartate aminotransferase (AST), alanine
                  aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), lactate
                  dehydrogenase (LDH), or alkaline phosphatase levels to greater than the upper
                  limit of normal (ULN);

              23. Positive test results for hepatitis B virus antibody, or hepatitis C virus
                  antibody at screening;

              24. Use of or need for any systemic drug(s) including vitamins or herbal preparations
                  other than drugs used for contraception, within 10 days before Study Day -1 or
                  during the study;

              25. Use of aspirin, non-steroidal anti-inflammatory agents, or acetaminophen within 5
                  days prior to the ingestion of the study drug; use of aspirin or non-steroidal
                  anti inflammatory agents (but not acetaminophen) will be allowed for isolated
                  episodes of pain at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

